Highlights and interviews from the American Society of Hematology’s Annual Meeting.
Eugenia Vicky Asare, MD: Multidisciplinary Care Saves Lives Among Pregnant Women with SCD in Ghana
Kenneth Ataga, MD: Crizanlizumab: A New Option for Managing Sickle Cell-Related Pain Crises?
Adam D. Cohen, MD: Expanding CAR T Cells to Treat Myeloma
Graham Jackson, MD: Lenalidomide Maintenance Is Effective in All Types of Myeloma Patients
Crystal Mackall, MD: Passing the Checkpoint With New Approaches to Immunotherapy
Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML
Steven Pipe, MD: Changing the Delivery of Bleeding Prevention for Hemophilia Patients
Sherrill J. Schlicter, MD: Prolonging Platelet Shelf-Life With DMSO
Not Just CRISPR: Changing Biology Through Gene-Editing
Sattva S. Neelapu, MD: Encouraging Results for CAR T-Cells in Refractory DLBCL
David Miklos, MD, PhD: Ibrutinib in Chronic Graft-Versus-Host Disease
Robert E. Marcus, MD: GALLIUM Study of Obinutuzumab in Untreated Follicular Lymphoma
John Mascarenhas, MD, MS: Continuing to Evaluate Pacritinib for Myelofibrosis
Anjali Advani, MD: Vadastuximab Talirine in Treatment-Naïve CD33-Positive AML
Dan T. Vogl, MD: Selinexor Plus Low-Dose Dexamethasone in “Penta-Refractory” Myeloma Patients
Martin Schrappe, MD: Attempting to Reduce Chemotherapy Burden in Children With ALL
Joan C. Gill, MD: New Recombinant Factors for von Willebrand Disease
Stephen M. Ansell, MD, PhD: Nivolumab Moves to Hematology
Is Rivaroxaban Safe as Long-Term Prevention for Deep-Vein Thrombosis?
Multiple Advances in Multiple Myeloma
What Was Hot at ASH 2015?
Rivaroxaban in Cancer-Associated VTE: Results from CALLISTO
Late-Breaking Abstract: RESONATE 2 Finds First-Line Ibrutinib Superior to Chlorambucil in CLL/SLL
The Balancing Act of Caring for Older Patients with Hemophilia
Ibrutinib Beats Temsirolimus in Relapsed/Refractory MCL
Improving Quality of VTE Care
The PROs of Patient-Reported Outcomes
Induction Chemotherapy for AML: Understanding the Patient Experience
Late-Breaking Abstract: First-in-Man Trial of CAR T Cells in Myeloma
Ixazomib Extends PFS in the TOURMALINE-MM1 Trial
Evolving Issues in Anticoagulation
Predicting Prognosis in Myelodysplastic Syndromes
New Approaches in CLL and Prolymphocytic Leukemia
Late-Breaking Abstract: Eltrombopag Improves Response in Severe Aplastic Anemia
Optimizing Therapy in Sickle Cell Disease
Controversy over Quality
Eligibility Criteria Not Associated with Adverse Events in RCTs
Newly Approved Drugs: How Should We Use Them in the Clinic?
Guiding Hematologic Care with Genetic Testing